Blood marker LRG and disease activity in Crohn's disease and ulcerative colitis
Studies how a blood protein, LRG, relates to disease activity in inflammatory bowel disease.
Plain-language title generated from the registry record
Registry title: Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Key facts
- Where
- Bonheiden, BelgiumSee the site
Where in Belgium
- Imelda General HospitalBonheiden, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Imelda GI Clinical Research Center
- Trial code
- NCT07621783
- Record updated
- 2 June 2026
- Original description
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.Read full original descriptionShow less
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context: LEADER Trial.
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
Inclusion: ≥18 years; Patient with confirmed diagnosis of IBD; Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice; willing to provide informed consent.
Exclusion: Patient with IBD unspecified; Patient with ileo- or colostomy; Patient with total colectomy; Women that are pregnant.